IGF2BP3 and hepatocellular carcinoma: This implies that compared to the control group, IGF2BP3-KD HCC cells exhibited reduced drug sensitivity to NC, providing evidence that the anti-HCC activity of NC is indeed through targeting IGF2BP3.